• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The pharmacokinetics of intravesical and oral oxybutynin chloride.

作者信息

Massad C A, Kogan B A, Trigo-Rocha F E

机构信息

Department of Urology, University of California School of Medicine, San Francisco.

出版信息

J Urol. 1992 Aug;148(2 Pt 2):595-7. doi: 10.1016/s0022-5347(17)36663-6.

DOI:10.1016/s0022-5347(17)36663-6
PMID:1640530
Abstract

In 8 children with cystometric evidence of bladder instability and marked systemic side effects to oral oxybutynin we investigated the efficacy of intravesical instillation and compared the pharmacokinetics of both routes of delivery. In addition, 4 healthy dogs underwent intravesical instillation for pharmacokinetic studies. Intravesical oxybutynin was well tolerated, efficacious and rapidly absorbed, resulting in plasma concentrations markedly higher than after oral administration. In only 2 patients did this method of instillation result in side effects, and both had previously undergone bladder augmentation. This lack of significant systemic side effects despite high plasma concentrations suggests that a metabolite may be generated after oral administration that is responsible for the side effects. These studies demonstrate that the mode of administration affects the mechanism of action, side effects, pharmacokinetics and metabolism of oxybutynin, and that intravesical instillation is clinically effective and results in minimal side effects.

摘要

相似文献

1
The pharmacokinetics of intravesical and oral oxybutynin chloride.
J Urol. 1992 Aug;148(2 Pt 2):595-7. doi: 10.1016/s0022-5347(17)36663-6.
2
Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder.
Br J Urol. 1998 Dec;82(6):859-64. doi: 10.1046/j.1464-410x.1998.00888.x.
3
Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.膀胱内注射奥昔布宁治疗神经源性膀胱功能障碍:由于首过代谢减少,全身副作用较少。
J Urol. 1998 Sep;160(3 Pt 1):892-6. doi: 10.1016/S0022-5347(01)62828-3.
4
Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.奥昔布宁膀胱内制剂在逼尿肌过度活动患者中的药代动力学、疗效及安全性。
Scand J Urol Nephrol. 2002 Feb;36(1):18-24. doi: 10.1080/003655902317259319.
5
Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results.奥昔布宁膀胱内给药:控制逼尿肌反射亢进的作用方式。初步结果。
Eur Urol. 1995;28(4):340-4. doi: 10.1159/000475078.
6
The use of intravesical oxybutynin chloride in children with neurogenic bladder.膀胱内注射氯化奥昔布宁在神经源性膀胱患儿中的应用。
J Urol. 1991 Aug;146(2 ( Pt 2)):532-4. doi: 10.1016/s0022-5347(17)37845-x.
7
[Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].[膀胱内注射奥昔布宁治疗脊髓脊膜膨出症患儿。疗效显著且副作用少]
Lakartidningen. 1996 Oct 9;93(41):3573-6.
8
Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity.神经源性膀胱功能障碍和膀胱容量减少患者膀胱内注入氯化奥昔布宁与间歇性清洁导尿术
Br J Urol. 1993 Nov;72(5 Pt 2):719-22. doi: 10.1111/j.1464-410x.1993.tb16255.x.
9
Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.盐酸奥昔布宁膀胱内灌注治疗神经源性膀胱患者。
Paraplegia. 1994 Jan;32(1):25-9. doi: 10.1038/sc.1994.5.
10
[Topical use of oxybutynin hydrochloride in women with urge incontinence].盐酸奥昔布宁在急迫性尿失禁女性中的局部应用
Gynakol Geburtshilfliche Rundsch. 1994;34(1):23-4. doi: 10.1159/000272324.

引用本文的文献

1
Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.治疗老年人下尿路症状:膀胱内治疗选择。
Drugs Aging. 2023 Mar;40(3):241-261. doi: 10.1007/s40266-023-01009-5. Epub 2023 Mar 6.
2
Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder.奥昔布宁的剂量变异性与临床结局:神经源性膀胱患儿的队列研究。
Top Spinal Cord Inj Rehabil. 2022 Summer;28(3):9-14. doi: 10.46292/sci21-00091. Epub 2022 Aug 17.
3
First North American experience of propiverine use in children with overactive bladder.
丙哌维林用于膀胱过度活动症儿童的首次北美经验。
Can Urol Assoc J. 2022 Oct;16(10):358-363. doi: 10.5489/cuaj.7811.
4
Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis.神经源性逼尿肌过度活动患者的膀胱内奥昔布宁治疗:一项系统评价和荟萃分析。
Int Urol Nephrol. 2022 Apr;54(4):737-747. doi: 10.1007/s11255-022-03129-0. Epub 2022 Feb 28.
5
A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study.一项随机交叉试验,比较非索罗定和缓释奥昔布宁在膀胱过度活动症儿童中的疗效和安全性,并对非索罗定进行为期12个月的延长期研究:FOXY研究。
Can Urol Assoc J. 2020 Jun;14(6):192-198. doi: 10.5489/cuaj.6247.
6
Overactive bladder in children.儿童膀胱过度活动症
Can Urol Assoc J. 2017 Jan-Feb;11(1-2Suppl1):S74-S79. doi: 10.5489/cuaj.4337.
7
The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity.长期药物治疗联合间歇性清洁导尿对神经源性逼尿肌过度活动症患儿的影响。
Int Urol Nephrol. 2012 Apr;44(2):335-41. doi: 10.1007/s11255-011-0030-y. Epub 2011 Jul 21.
8
A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.氯化奥昔布宁制剂的比较综述:膀胱过度活动症的药代动力学和治疗效果
Rev Urol. 2010 Winter;12(1):12-9.
9
The evolution of transdermal therapy for overactive bladder.膀胱过度活动症经皮治疗的进展
Curr Urol Rep. 2009 Sep;10(5):338-41. doi: 10.1007/s11934-009-0053-4.
10
Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.丙哌维林溶液以及速释和缓释剂型的口服吸收:区域选择性肠道消除的影响
Eur J Clin Pharmacol. 2008 Nov;64(11):1085-92. doi: 10.1007/s00228-008-0528-0. Epub 2008 Jul 15.